EUCTR2013-004657-24-GB进行中（未招募）1 期
A randomised, double-blind, placebo controlled, feasibility study exploring the role of Chinese herbal medicine in the treatment of women with recurrent urinary tract infections. - CHM for RUTIs
Southampton University0 个研究点目标入组 80 人开始时间: 2014年9月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Women will be eligible for the trial if they are aged over 18 and under 65 years of age and have reported 3 or more uncomplicated recurrent lower UTIs in the previous 12 months where at least one episode has been documented as bacterial UTI.
- •The reason for the upper age limit of 65 years is that Chinese medicine differentiates several different diagnostic patterns relating to RUTIs. The herbal formulae used for this trial have been designed for a pattern more common in women aged under 65 years. Women over the age of 65 will tend to present with a different pattern to a younger age group and therefore the standardised formula may not be appropriate for them.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Women will be excluded from the trial if they have symptoms of complicated UTI’s such as acute pyelonephritis; have known hepatic or renal disease; are pregnant or breast feeding; have diabetes; have commenced a new treatment for RUTIs in the previous 6 months; are taking drugs which may interact with Chinese herbal medicine: cardiac glycosides (Digoxin), warfarin and lithium; have psychosis, dementia or terminal illness that may prevent completion of symptom diaries. During the trial women will be excluded if they develop significantly raised liver (ALT > 90 U/l) or renal function tests (GFR < 90 mL/mm/1.73m2). Any women who also become pregnant during the trial will also be advised to stop taking the CHM and to inform a member of the study team for further advice. If pregnancy is confirmed, the participant will be asked to withdraw from the intervention in the study and asked for their consent to remain for safety monitoring purposes.
研究者
相似试验
已完成
3 期
A placebo-controlled trial to assess the effect of aspirin and fish oil (omega-3 fatty acids) in the prevention of early thrombosis in arterio-venous fistulae in patients with chronic kidney disease requiring haemodialysisEarly thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysisRenal and Urogenital - Kidney diseaseACTRN12607000569404Australasian Kidney Trials Network657
进行中（未招募）
不适用
A randomized, double-blind, placebo- controlled, flexible dose study to evaluate the effectiveness and safety of pramipexole IR (0.125 – 0.5mg/day) compared to placebo for 6 weeks in children and adolescents (age 6-17 years) who are diagnosed with Tourette’s DisorderTourette's SyndromeMedDRA version: 14.0Level: LLTClassification code 10044127Term: Tourette's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-004460-39-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.54
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-17 inclusive) diagnosed with Tourette Disorder according to DSM-IV criteriaEUCTR2008-004460-39-DEBoehringer Ingelheim Pharma GmbH & Co. KG54
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1 Level: PT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependentEUCTR2005-004597-24-GBBoehringer Ingelheim Limited375
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-SEBoehringer Ingelheim AB500